Alpha Tau Submits First FDA Pre-Market Approval Module for Alpha DaRT® in cSCC
Summary
Alpha Tau Medical announced the submission of the first module of its Pre-Market Approval (PMA) application to the FDA for its Alpha DaRT® therapy for recurrent cutaneous squamous cell carcinoma (cSCC), marking a key regulatory milestone.
Key Events
-
First PMA Module Submitted
Alpha Tau Medical submitted the initial module of its Pre-Market Approval (PMA) application to the FDA for Alpha DaRT® for recurrent cutaneous squamous cell carcinoma (cSCC).
-
Modular Review Process
The FDA granted a flexible modular submission framework, allowing for streamlined review and feedback as each module is submitted.
-
Breakthrough Device Designation
Alpha DaRT® holds Breakthrough Device Designation from the FDA for this indication, potentially accelerating its path to market.
-
Pivotal Study Progress
The pivotal ReSTART study for recurrent cSCC is ongoing, with patient recruitment anticipated to conclude in Q1 2026.
Analysis
This submission represents a significant step towards potential market authorization for Alpha Tau's Alpha DaRT® therapy. The FDA's flexible modular submission framework allows for ongoing review and feedback, which could expedite the approval process. The therapy has already received Breakthrough Device Designation for this indication, further highlighting its potential. Investors should monitor subsequent module submissions and the progress of the pivotal ReSTART study, which is expected to complete patient recruitment in Q1 2026, as these are critical milestones for commercialization.
At the time of this filing, DRTS was trading at $4.94 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $411.8M. The 52-week trading range was $2.30 to $5.21. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.